KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki Sells 5,779 Shares

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the completion of the sale, the chief executive officer now directly owns 280,076 shares of the company’s stock, valued at $2,136,979.88. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

KALA BIO Trading Up 2.1 %

KALA BIO stock opened at $7.69 on Wednesday. The business has a 50 day moving average price of $6.71 and a two-hundred day moving average price of $6.32. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO, Inc. has a 12 month low of $4.21 and a 12 month high of $9.25. The stock has a market cap of $35.45 million, a price-to-earnings ratio of -0.62 and a beta of -2.11.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. As a group, equities analysts forecast that KALA BIO, Inc. will post -10.84 EPS for the current year.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a report on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.